Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 74

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 74
---
We may need to raise additional capital to fund our existing operations, develop additional products and services, commercialize new products and services or expand our operations. 

Based on our current business plan, we believe our current cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements over at least the next 12 months. If our available cash and investment balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of lower demand for our products and services as a result of risks described herein, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. 

We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to: 

•increase our sales and marketing efforts to drive market adoption of our life sciences research, clinical diagnostics and therapeutics; 

•fund development efforts for our current and future products and services; 

•expand our products and services into other disease indications and clinical applications; 

•acquire, license or invest in technologies; 

•acquire or invest in complementary businesses or assets; and 

•finance capital expenditures, such as our corporate headquarters expansion, and general and administrative expenses. 

Our present and future funding requirements will depend on many factors, including: 

•our ability to achieve revenue growth; 

•our rate of continued progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors for our clonoSEQ diagnostic test; 

•the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts; 

•our rate of progress in supporting the development of cellular therapies developed under the Genentech Agreement; 

•our rate of progress in, and research and development expenses associated with, products and services in research and early development; 

•the effect of competing technological, product and market developments; 

•costs related to international expansion; and 

•the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products and services. 

41

The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have